Diagnosis and management of primary central nervous system lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Primary central nervous system lymphoma is a clinicopathological disease entity that accounts for 1% of all non‐Hodgkin lymphoma (NHL). Advanced patient age, adverse disease biology and complexities of diagnosis and treatment render outcomes markedly inferior to systemic NHL. Despite this, an increa...

Full description

Saved in:
Bibliographic Details
Published in:Internal medicine journal 2022-09, Vol.52 (9), p.1624-1632
Main Authors: Keane, Colm, Hamad, Nada, Barraclough, Allison, Lee, Yoo Y., Talaulikar, Dipti, Ku, Matthew, Wight, Joel, Tatarczuch, Maciej, Swain, Fiona, Gregory, Gareth P.
Format: Article
Language:English
Subjects:
Central nervous system
Chemotherapy
CNS
Diagnosis
Literature reviews
lymphoma
Methotrexate
Non-Hodgkin's lymphoma
Patients
PCNSL
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Primary central nervous system lymphoma is a clinicopathological disease entity that accounts for 1% of all non‐Hodgkin lymphoma (NHL). Advanced patient age, adverse disease biology and complexities of diagnosis and treatment render outcomes markedly inferior to systemic NHL. Despite this, an increasing evidence base, including limited randomised controlled clinical trial data, is informing optimal therapeutic strategies with methotrexate‐based induction chemotherapy schedules and intensified consolidation in selected patients. This practice statement represents an evidence‐based review of the literature and has been devised to assist healthcare professionals in the diagnosis and management of this disease.
ISSN:1444-0903
1445-5994
DOI:10.1111/imj.15658